Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 55OTHER 23NIH 1NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 213Carcinoma, Non-Small-Cell Lung 148Lung Neoplasms 128Lymphoma 119Prostatic Neoplasms 115Leukemia 102Ovarian Neoplasms 100Central Nervous System Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 89Colorectal Neoplasms 89Head and Neck Neoplasms 87Sarcoma 84Multiple Myeloma 80Squamous Cell Carcinoma of Head and Neck 73Rectal Neoplasms 62Leukemia, Myeloid, Acute 62Carcinoma, Ovarian Epithelial 61Uterine Cervical Neoplasms 60Neoplasm Metastasis 59Brain Neoplasms 57Colonic Neoplasms 56Fallopian Tube Neoplasms 53Astrocytoma 53Lymphoma, Large B-Cell, Diffuse 50Glioblastoma 49Burkitt Lymphoma 47Urinary Bladder Neoplasms 46Melanoma 45Neuroblastoma 44Hodgkin Disease 44

Interventions

neratinib 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Interventional × Hereditary Sensory and Autonomic Neuropathies × Clear all
NCT01960023 2021-10-27

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

NSABP Foundation Inc

Phase 1/2 Withdrawn
Gastrointestinal

Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡